RION, a commercial and clinical-stage regenerative medicine company, has engaged Lonza, a contract development and manufacturing organization (CDMO), to provide cGMP manufacturing and technical support for commercial-scale production of Rion’s Purified Exosome Product (PEP) drug substance for late phase clinical supply and beyond. RION has developed a proprietary biomanufacturing platform enabling scaled production of platelet-derived exosomes. Under the terms of the agreement, Lonza will man...